Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) Net Margin (2016 - 2025)

Voyager Therapeutics' Net Margin history spans 11 years, with the latest figure at 178.83% for Q4 2025.

  • For Q4 2025, Net Margin rose 37050.0% year-over-year to 178.83%; the TTM value through Dec 2025 reached 296.53%, down 17482.0%, while the annual FY2025 figure was 296.53%, 21528.0% down from the prior year.
  • Net Margin for Q4 2025 was 178.83% at Voyager Therapeutics, up from 209.12% in the prior quarter.
  • Across five years, Net Margin topped out at 1524.26% in Q4 2022 and bottomed at 3239.97% in Q1 2022.
  • The 5-year median for Net Margin is 365.68% (2024), against an average of 594.04%.
  • The largest annual shift saw Net Margin plummeted -284665bps in 2022 before it surged 332240bps in 2023.
  • A 5-year view of Net Margin shows it stood at 20.34% in 2021, then soared by 7395bps to 1524.26% in 2022, then tumbled by -96bps to 62.62% in 2023, then tumbled by -977bps to 549.33% in 2024, then skyrocketed by 67bps to 178.83% in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Net Margin are 178.83% (Q4 2025), 209.12% (Q3 2025), and 641.96% (Q2 2025).